JS
James Sapirstein
Chairman and CEODirector

James Sapirstein insider trades: Entero Therapeutics (ENTO) stock buys and sales

Chairman and CEO, Entero Therapeutics Last trade Jul 2, 2024 48 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2015
17
Companies
last trade 2024

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where James reports to the SEC

and 11 more companies

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 2, 2024ENTO↓ Sell$1K
Apr 1, 2024FWBI↓ Sell$736
Mar 15, 2024FWBI↓ Sell$9K
Jan 12, 2024FWBI↓ Sell$697
Oct 4, 2023FWBI↓ Sell$802
Jul 3, 2023FWBI↓ Sell$5K
Apr 3, 2023FWBI↓ Sell$8K
Feb 18, 2016CTRV↑ Buy$10K
Nov 30, 2015CTRV↑ Buy$1K
Nov 23, 2015CTRV↑ Buy$4K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About James Sapirstein's insider trades

James Sapirstein is Chairman and CEO at Entero Therapeutics (ENTO). Since Nov 23, 2015, James has reported 3 open-market purchases worth $15K and 7 sales worth $26K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (36 filings), other transactions (2 filings), shares withheld for taxes (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ENTO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.